TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12432838

Group type: COMPARATOR
Intervention: Presence of anti‐Helicobacter pylori antibodies (anti‐HP Ab) in women with vomiting (162 women)
Number of subjects: 3438

Group type: COMPARATOR
Intervention: Presence of anti‐Helicobacter pylori antibodies (anti‐HP Ab) in women with severe emesis (250 women)
Number of subjects: 3438
Study: 10707114

Group type: EXPERIMENTAL
Intervention: Ibuprofen with diazepam administered at 22.00 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ibuprofen alone administered at 22.00 hours
Number of subjects: 8
Study: 9167559

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8466725

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg twice daily)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Felodipine (2.5 mg twice daily)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 143
Study: 2869027

Group type: EXPERIMENTAL
Intervention: trihexyphenidyl (N = 15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo (N = 27)
Number of subjects: 42
Study: 30452665

Group type: EXPERIMENTAL
Intervention: Face-to-face F-PST
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Therapist-guided online F-PST
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-guided online F-PST
Number of subjects: 150

Group type: COMPARATOR
Intervention: Therapist-involved approaches (face-to-face and therapist-guided online)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 150
Study: 29964324

Group type: COMPARATOR
Intervention: D2 laparoscopic distal gastrectomy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: D2+ CME laparoscopic distal gastrectomy
Number of subjects: 161
Study: 27893068

Group type: EXPERIMENTAL
Intervention: 2 doses of the 9-valent HPV vaccine (6 months apart)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: 2 doses of the 9-valent HPV vaccine (12 months apart)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: 3 doses of the 9-valent HPV vaccine (6 months apart)
Number of subjects: 1518
Study: 24170263

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg p.o. alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Imatinib 400 mg p.o. with 4,000 mg calcium carbonate (Tums Ultra) administered 15 min before
Number of subjects: 11
Study: 23164965

Group type: EXPERIMENTAL
Intervention: Corpitolinol 60
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (usual measures for preventing pressure sores)
Number of subjects: 301
Study: 20051731

Group type: EXPERIMENTAL
Intervention: One-leg cycling (OLC) aerobic training program with the untreated leg plus a rehabilitation program (training group, TG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rehabilitation program without aerobic training (control group, CG)
Number of subjects: 24
Study: 19192865

Group type: EXPERIMENTAL
Intervention: Prize contingency management for smoking cessation (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care for smoking cessation (n=12)
Number of subjects: 24
Study: 15793663

Group type: EXPERIMENTAL
Intervention: MCH-3' (3-minute interval methacholine challenge test)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: MCH-5' (5-minute interval methacholine challenge test)
Number of subjects: 52

Group type: COMPARATOR
Intervention: MCH-3' and MCH-5'
Number of subjects: 52
Study: 12453124

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Titanium plasma-flame (TPF) coating
Number of subjects: 313

Group type: COMPARATOR
Intervention: Both coatings (HA and TPF)
Number of subjects: 313
Study: 9841760

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) 300 IU/kg on day 4 before surgery and 150 IU/kg daily for 7 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 81
Study: 7783099

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 25
Study: 8404359

Group type: EXPERIMENTAL
Intervention: Topical timolol and indomethacin
Number of subjects: 40
Study: 2860179

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 60% n-propanol
Number of subjects: 0
Study: 30057060

Group type: EXPERIMENTAL
Intervention: Chamomile essence (aromatherapy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no chamomile essence)
Number of subjects: 130
Study: 27776598

Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EbV) treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Complex second-line treatment (control)
Number of subjects: 102
Study: 24317232

Group type: EXPERIMENTAL
Intervention: SPEDI technique (15 mL of ropivacaine 0.75% around the sciatic nerve and 5 mL of ropivacaine 0.75% at the saphenous nerve)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Popliteal-sciatic/saphenous technique
Number of subjects: 60
Study: 21939399

Group type: EXPERIMENTAL
Intervention: Training tasks performed with the non-dominant hand for three weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific training tasks)
Number of subjects: 26
Study: 20421242

Group type: EXPERIMENTAL
Intervention: MIRA Standard of Care program (additional counseling and clinical care)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: MIRA Standard of Care program (referrals to government healthcare facilities)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: MIRA Standard of Care program (enrollment in wellness/treatment programs)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: MIRA Standard of Care program (declined further care)
Number of subjects: 323
Study: 18572029

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study: 16051910

Group type: EXPERIMENTAL
Intervention: Consumer-directed care (treatment group)
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Traditional agency services (control group)
Number of subjects: 1433
Study: 12132030

Group type: EXPERIMENTAL
Intervention: Angioseal
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Vasoseal
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Duett
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Angioseal, Vasoseal, Duett
Number of subjects: 851
Study: 10599715

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 106
Study: 7551613

Group type: EXPERIMENTAL
Intervention: Combined live+imagined exposure/ritual prevention (Exi)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Only live exposure/ritual prevention (Ex)
Number of subjects: 46
Study: 1791078

Group type: EXPERIMENTAL
Intervention: 2 g cefotaxime i.v. plus 200 mg ofloxacin twice daily (group 1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 2 g cefotaxime i.v. twice daily plus tobramycin i.v. three times daily (group 2)
Number of subjects: 87
Study: 6969937

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical neurostimulation (TENS)
Number of subjects: 0
Study: 30805617

Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine (SSD) dressing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polylactic membrane (PLM) dressing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydrofiber with silver (HFAg) dressing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 28688822

Group type: EXPERIMENTAL
Intervention: Viewing high-calorie food pictures
Number of subjects: 40
Study: 26378939

Group type: EXPERIMENTAL
Intervention: Patient empowerment through information booklet and diary keeping
Number of subjects: 652

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 652
Study: 23361056

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening preferences
Number of subjects: 1000
Study: 21350928

Group type: EXPERIMENTAL
Intervention: Triazolam (0.12 mg/70 kg) + Progesterone (100 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg) + Progesterone (200 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Progesterone alone (100 mg and 200 mg)
Number of subjects: 11
Study: 19628958

Group type: EXPERIMENTAL
Intervention: Individual narrative exposure therapy (NET, n=12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group adaptation of interpersonal psychotherapy (IPT, n=14)
Number of subjects: 26
Study: 17374660

Group type: EXPERIMENTAL
Intervention: LTP-enriched yogurt beverage
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15098169

Group type: EXPERIMENTAL
Intervention: TCI-TIVA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MAN-TIVA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BAL-SEVO
Number of subjects: 51
Study: 11216756

Group type: EXPERIMENTAL
Intervention: Antegrade crystalloid cardioplegia (group A, n = 29)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Retrograde crystalloid cardioplegia (group R, n = 29)
Number of subjects: 58
Study: 9798655

Group type: EXPERIMENTAL
Intervention: IST plus recombinant human erythropoietin and granulocyte‐macrophage colony‐stimulating factor (rhEPO + rhGM‐CSF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: IST alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ALG plus HGFs
Number of subjects: 38
Study: 7886971

Group type: EXPERIMENTAL
Intervention: molsidomin (2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: molsidomin (2 mg) and ondansetron (8 mg)
Number of subjects: 10
Study: 2974775

Group type: EXPERIMENTAL
Intervention: Humulin‐Zn
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Neulente insulin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-insulin treated patients
Number of subjects: 22
Study: 29626313

Group type: EXPERIMENTAL
Intervention: Depressed mood state induction in asthma group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Neutral mood state induction in asthma group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Depressed mood state induction in healthy controls
Number of subjects: 84

Group type: COMPARATOR
Intervention: Neutral mood state induction in healthy controls
Number of subjects: 84
Study: 28237955

Group type: EXPERIMENTAL
Intervention: Nurse-led facilitated advance care planning intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study: 26188380

Group type: EXPERIMENTAL
Intervention: Preventive Cognitive Therapy (PCT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 172
Study: 22930656

Group type: EXPERIMENTAL
Intervention: Self-help treatment (Deprexis)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 210
Study: 20386359

Group type: EXPERIMENTAL
Intervention: Gene-based dosing algorithm
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard of care dosing
Number of subjects: 229
Study: 18179471

Group type: EXPERIMENTAL
Intervention: Preventive dental services in medical offices
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Baseline preventive dental visit at a younger age
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Caregivers reporting greater numbers of children and putting the child to bed with the bottle
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Older age of child, male child, caregiver education ≤ 12 years
Number of subjects: 744
Study: 16617916

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 14763702

Group type: EXPERIMENTAL
Intervention: Daily pin site care (n = 27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Weekly pin site care (n = 23)
Number of subjects: 50
Study: 10808698

Group type: EXPERIMENTAL
Intervention: Serum CYFRA 21-1
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum CEA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of CYFRA 21-1 and CEA
Number of subjects: 51

Group type: COMPARATOR
Intervention: Patients with benign lung diseases
Number of subjects: 51
Study: 8848646

Group type: EXPERIMENTAL
Intervention: Modified supraclavicular technique (group 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Axillary perivascular technique (group 1)
Number of subjects: 100
Study: 1599986

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.1 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 6
Study: 4040421

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 100
Study: 31387013

Group type: EXPERIMENTAL
Intervention: Shame condition
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 88
Study: 30043415

Group type: EXPERIMENTAL
Intervention: Music therapy during hospitalisation (twice a week for four to six weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group received no music therapy during hospitalisation, intervention after discharge
Number of subjects: 29
Study: 26645391

Group type: EXPERIMENTAL
Intervention: Brief intervention (BI) by trained general practitioners
Number of subjects: 60

Group type: COMPARATOR
Intervention: Business as usual (BAU)
Number of subjects: 60
Study: 24825078

Group type: EXPERIMENTAL
Intervention: Methylphenidate (45 mg, single oral dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 24
Study: 21788248

Group type: EXPERIMENTAL
Intervention: Magnetic field therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 50
Study: 20456191

Group type: EXPERIMENTAL
Intervention: Menthol 10% solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (0.5% ethanol solution of menthol)
Number of subjects: 35
Study: 17062582

Group type: EXPERIMENTAL
Intervention: GnRH antagonist group (n=148)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (n=151)
Number of subjects: 299
Study: 15748121

Group type: EXPERIMENTAL
Intervention: Chronic post-stroke subjects
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 21
Study: 12088960

Group type: EXPERIMENTAL
Intervention: Pain Matcher
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Electro‐acupuncture
Number of subjects: 223

Group type: COMPARATOR
Intervention: Alfentanil (fast‐acting opiate)
Number of subjects: 223
Study: 10500938

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Endotracheal Tube (ETT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (LMA and ETT)
Number of subjects: 56
Study: 8759495

Group type: EXPERIMENTAL
Intervention: Octreoscan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MIBG
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: I131-MIBG
Number of subjects: 18
Study: 1746997

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 6181331

Group type: EXPERIMENTAL
Intervention: Standard amitriptyline (75 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained-release amitriptyline (75 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard amitriptyline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sustained-release amitriptyline
Number of subjects: 8
Study: 31535806

Group type: EXPERIMENTAL
Intervention: Silodosin plus Androgel 1% topically
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silodosin (monotherapy)
Number of subjects: 60
Study: 30501871

Group type: EXPERIMENTAL
Intervention: Imatinib 300 mg/m2 continuously from day 15 of induction during chemotherapy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 155
Study: 26656144

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 858

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Follow-up sST2 levels
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Baseline sST2 levels
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Persistently high sST2 levels (>60 ng/ml) at follow-up
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Baseline and follow-up sST2 levels
Number of subjects: 858
Study: 24288691

Group type: EXPERIMENTAL
Intervention: Transnasal EGD (UT group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard endoscope (SO group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Thin endoscope (UO group)
Number of subjects: 165
Study: 23017309

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules daily for 8 weeks, each containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20816912

Group type: EXPERIMENTAL
Intervention: 200mg of caffeine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17620054

Group type: EXPERIMENTAL
Intervention: 0.014 mg/d transdermal estradiol patch
Number of subjects: 382
Study: 15161389

Group type: EXPERIMENTAL
Intervention: Singleton (square frame) inserted between targets during rapid serial visual presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Singleton containing the key target feature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Singleton not possessing the key target feature
Number of subjects: 0
Study: 11673342

Group type: EXPERIMENTAL
Intervention: Plasma ghrelin in CHF patients with cachexia (n=28)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Plasma ghrelin in CHF patients without cachexia (n=46)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Plasma ghrelin in all CHF patients (n=74)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Plasma ghrelin in control subjects (n=12)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Circulating GH in CHF patients with cachexia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Circulating TNF-alpha in CHF patients with cachexia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with GH
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with TNF-alpha
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation of plasma ghrelin with body mass index
Number of subjects: 74
Study: 9849454

Group type: EXPERIMENTAL
Intervention: IVA (ifosfamide, vincristine and actinomycin D) for patients with completely resected primary tumour (3 courses)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: IVA (ifosfamide, vincristine and actinomycin D) for patients with incompletely resected tumour (6 to 10 courses)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Local therapy (surgery +/- radiotherapy) for patients remaining in partial remission
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Limited surgery followed by three courses of IVA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (after initial biopsy)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus conservative local treatment (limited surgery or radiotherapy for residual disease)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Intensive local therapy (radical wide field radiotherapy or radical surgery or both)
Number of subjects: 186
Study: 7926134

Group type: EXPERIMENTAL
Intervention: KTP/532 laser laparoscopy (neosalpingostomy)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: KTP/532 laser laparoscopy (salpingostomy)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Bilateral neosalpingostomy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Bilateral salpingostomy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patients with endometriosis
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Patients without endometriosis but with other infertility factors
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ectopic pregnancies
Number of subjects: 113
Study: 2808258

Group type: EXPERIMENTAL
Intervention: Methylphenidate (double-blind trial)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No intervention (control group without ANX)
Number of subjects: 79
Study: 798586

Group type: EXPERIMENTAL
Intervention: ifosfamide (Holoxan) administered as massive-dose treatment, daily dosage of 50 to 60 mg/kg on 5 consecutive days
Number of subjects: 390

Group type: COMPARATOR
Intervention: ifosfamide (Holoxan)
Number of subjects: 390
Study: 30940132

Group type: EXPERIMENTAL
Intervention: MOVIE intervention plus standard of care (SoC) provided by mentor-mothers (community health workers)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Standard of care (SoC) provided by mentor-mothers (community health workers)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: MOVIE intervention plus standard of care (SoC)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 1008
Study: 29077146

Group type: COMPARATOR
Intervention: Conventional treatment group (45 patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional rosuvastatin dose group (45 patients, 10 mg/d)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Large rosuvastatin dose group (47 patients, 20 mg/d)
Number of subjects: 137
Study: 26243579

Group type: EXPERIMENTAL
Intervention: Final kissing inflation (FKI)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Leave-alone strategy
Number of subjects: 514

Group type: COMPARATOR
Intervention: Crush technique
Number of subjects: 514
Study: 23847491

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 21663427

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8-12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group without medication
Number of subjects: 67